Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Study Shows Thymic Health is Linked to Cancer Patients’ Response to... October 16, 2025 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma May 23, 2023 Load more HOT NEWS Breaking down changes in NHS cancer waiting times in England Colon capsule endoscopy – reshaping bowel cancer diagnosis ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease...